Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTBVAC-203 in newborns for tuberculosis prevention
PACTR202111682972355Phase 3Recruiting
- Sponsor
- Biofabri
- Start
- Jan 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 3
01
Overview
Phase 3, randomised trial of mtbvac in Tuberculosis (TB) (2 arms), sponsored by Biofabri. Primary endpoint: Efficacy against tuberculosis disease. Started Jan 2022; status: recruiting.
02
Drugs
mtbvac
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202111682972355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202111682972355.